INmune Bio (INMB, Financial) received a notable rating downgrade from BTIG, with analyst Thomas Shrader changing the stock's rating from "Buy" to "Neutral". This decision marks a shift in the analyst’s stance, as there are no adjustments reported to the price target for INMB at this time.
The change was announced on July 1, 2025. No further details about the rationale behind the downgrade were provided in the report. The market will be closely watching INMB for any subsequent moves that may follow this adjustment.
For investors tracking INMB, it's important to note that the current rating reflects a more cautious outlook from BTIG compared to their prior assessment.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 5 analysts, the average target price for INmune Bio Inc (INMB, Financial) is $23.40 with a high estimate of $30.00 and a low estimate of $20.00. The average target implies an upside of 1,047.06% from the current price of $2.04. More detailed estimate data can be found on the INmune Bio Inc (INMB) Forecast page.
Based on the consensus recommendation from 5 brokerage firms, INmune Bio Inc's (INMB, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for INmune Bio Inc (INMB, Financial) in one year is $1.17, suggesting a downside of 42.65% from the current price of $2.04. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the INmune Bio Inc (INMB) Summary page.
